SeaStar Medical Holding Corporation
ICUHealthcare|Biotechnology|US
$1.88
-0.04 (-2.08%)
DCF Value
$3.08
Tangible Book / Share
$1.05
Cash / Share
$1.70
Clinical Trials (7)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT03836482 Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD | Acute on Chronic Systolic Congestive Heart Failure, Cardiorenal Syndrome | N/A | Recruiting | 20 | Open-label | — |
| NCT05758077 Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury | Acute Kidney Injury | N/A | Recruiting | 339 | RCT, Open-label | — |
| NCT06517810 QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry | Acute Kidney Injury, Acute Kidney Injury Due to Sepsis | Recruiting | 50 | — | — | |
| NCT01072682 Safety Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Renal Failure | Acute Renal Failure | N/A | Completed | 35 | Open-label | — |
| NCT04537975 C2Rx Hemofiltration Treatment in Severe or Critically Ill Adults With COVID-19 | Continuous Renal Replacement Therapy, Pulmonary Edema | N/A | Withdrawn | — | RCT, Open-label | — |
| NCT01400893 Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury | Acute Kidney Injury | N/A | Terminated | 134 | RCT, Open-label | — |
| NCT04395911 Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections | AKI, ARDS | N/A | Completed | 22 | Open-label | — |